ANHYDRON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Anhydron, and when can generic versions of Anhydron launch?
Anhydron is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in ANHYDRON is cyclothiazide. Additional details are available on the cyclothiazide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ANHYDRON?
- What are the global sales for ANHYDRON?
- What is Average Wholesale Price for ANHYDRON?
Summary for ANHYDRON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 57 |
| Patent Applications: | 1,226 |
| DailyMed Link: | ANHYDRON at DailyMed |
US Patents and Regulatory Information for ANHYDRON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | ANHYDRON | cyclothiazide | TABLET;ORAL | 013157-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
